ARX-1796 (AV-006), an Avibactam prodrug, is an orally bioavailable β-lactamase inhibitor. Avibactam has a spectrum of inhibition of class A and C β-lactamases, including ESBLs, AmpC and Klebsiella pneumoniae carbapenemase (KPC) enzymes.

Hikizimycin is a potent anthelmintic and antibacterial natural product.

Decamethoxine (Septefril) is a cationic gemini surfactant. Decamethoxine exhibits strong bactericidal and fungicidal effects. Decamethoxine modifies the permeability of the microbial cell membrane, resulting in the destruction and death of diverse microorganisms.

Debneyol exhibits more potent fungicidal activity than validamycin.

Fungicide4 shows the high activity against the P. infestans strain.

Benzyl 2-hydroxy-6-methoxybenzoate shows the strongest antifungal effect, with IC50 of 25–26 μg/mL for both fungal strains.

Fungicide5 is a fungicide candidate targeting succinate dehydrogenase (Ki = 0.095 μM).

Antiviral agent 9 reaches a single-digit picomolar EC50 value (0.006 nM) against HIV-1 and nearly 300-fold higher selectivity index (SI) compared to tenofovir alafenamide fumarate (TAF).

HIV-1 inhibitor-9 is found to be potent inhibitor against the wild-type (WT) HIV-1 strain or multiple NNRTI-resistant strains at low nanomolar levels.

Antimalarial agent 3 shows nanomolar antiplasmodial activity (IC50 = 0.035 μM) and has a very high selectivity index with respect to mammalian cells.

Antimalarial agent 2 is a novel orally efficacious antimalarials that suggests a fast in vitro killing profile.

BRD5018 is an antimalarial agent.

Carpaine is an alkaloid isolated from Carica papaya Linn with anti-thrombocytopenic activity, exhibits potent activity in sustaining platelet counts with no acute toxicity. Carpaine has anti-plasmodial activity to prevent malaria.

IQP-0528 is a highly potent nonnucleoside reverse transcriptase inhibitor (NNRTI). IQP-0528 shows nanomolar activity against both HIV-1 and HIV-2, with an HIV-1 EC50 of 0.2 nM and an HIV-2 EC50 of 100 nM.

Cichoriin is an active compounds against SARS-CoV-2, and may be a potential candidate in treating severe COVID-19.

Antibacterial agent 62 is a novel redox cycling antituberculosis chemotype with potent bactericidal activity against growing and nutrient-starved phenotypically drug-resistant nongrowing bacteria.

Anti gram-positive/negative bacteria agent 1 is an antibiotic conjugate with an artificial MECAM-based siderophore.

Antibacterial agent 63, a conjugate of aztreonam to a siderophore mimetic, shows activity against gram-negative bacteria.

(8'α,9'β-Dihydroxy)-3-farnesylindole shows strong inhibitory activity (EC50 9.8 μM) against B. subtilis.

Antibacterial agent 31 shows the antibacterial activity against rice bacterial leaf streak.

Antibacterial agent 30 demonstrates excellent in vitro activity against Xoo with EC50 value of 1.9 μg/mL.

Antibacterial agent 28 is a potential antibacterial candidate for combating MRSA infections (MICs = 0.5–2 μg/mL).

Antifungal agent 11 shows the promising antifungal activity.

Antifungal agent 12 is a novel fluconazole-based compound with promising antifungal activities.

Antifungal agent 16 displays considerable antibacterial activity and superior antifungal activity with reference to ciprofloxacin and fluconazole, respectively.

Antifungal agent 17 exhibits excellent antifungal properties against B. cinerea with an EC50 value of 2.86 μg/mL.

Antifungal agent 19 shows the potent antifungal activity (EC50 = 0.72 μM).

Antifungal agent 13 exhibits remarkable antifungal activity against Sclerotinia sclerotiorum with an EC50 value of 1.25 mg/L.

Antifungal agent 14 exhibits broad-spectrum activity against the fungal strains with excellent minimum inhibitory concentration values.

Antifungal agent 15 has the most potent activity with EC50 values of 0.52 and 0.50 μg/mL against S. sclerotiorum and B. cinerea, respectively.